Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1996-04-05
1998-11-17
Elliott, George C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
435238, 435375, 514 44, C07H 2100, A61K 3170, C12N 510
Patent
active
058378545
ABSTRACT:
Oligonucleotides that inhibit Epstein-Barr virus functions, pharmaceutical compositions containing such oligonucleotides, and methods of using these compositions to treat Epstein-Barr virus-associated diseases.
REFERENCES:
patent: 5194428 (1993-03-01), Agarawal et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5550047 (1996-08-01), Mulder
patent: 5585479 (1996-12-01), Hoke et al.
Crystal "Transfer of genes to humans:Early lessons and obstacles to success" Science 270: 404-410, Oct. 1995.
Gewirtz et al. "Facilitating oligonucleotide delivery: Helping antisnese deliver on its promise" Proc. Natl. Acad. Sci. USA 93: 3161-3163, Apr. 1996.
Gura "Antisense for growing pains" Science 270: 575-577, Oct. 1995.
Stull et al. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects Pharm Res. 12: 465-483, Apr. 1995.
"Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" Orkin and Motulsky, co-chairs. National Institutes of Health, Dec. 1997.
Agrawal et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. 85:7079-7083, 1988.
Baer et al., "DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome", Nature 310:207-211, 1984.
Biggin et al., "Epstein-Barr Virus Gene Expression in P3HR1-Superinfected Raji Cells", J. Virology 61;3120, 1987.
Cheung et al., "Unexpected Patterns of Epstein-Barr Virus Gene Expression During Early Stages of B Cell Transformation", International Immunology 5:707-716, 1993.
Chevallier-Greco et al., "Both Epstein-Barr Virus (EBV)-encoded Trans-acting Factors EBI and EB2, Are Required to Activate Transcription From an EBV Early Promoter", The EMBO Journal 5:3243-4249, 1986.
Daibata et al., "Antisense Oligodeoxynucleotides Against the BZLF1 Transcript Inhibit Induction of Productive Epstein-Barr Virus Replication", Antiviral Research 29:243-260, 1996.
Kevn, E. R., (1990) In: Antiviral Agents and Viral Diseases of Man, GJ Galass et al eds. pp. 94-95.
Pagano et al., "Epstein-Barr Viral Latency and Cell Immoratalization as Targets for Antisense Oligomers", Annals of The New York Academy of Sciences 660:107-116, 1992.
Roth et al., "Epstein-Barr Viral Nuclear Antigen 1 Antisense Oligodeoxynucleotide Inhibits Proliferation of Epstein-Barr Virus-Immortalized B Cells", Blood 84:582-587, 1994.
Tsubota et al., "Inhibited LMP Expression of EBV-Immortalized Lymphoblastoid Cells By Antisense Oligonucleotides", Investigative Ophthalmology & Visual Science 36:s992, Abstract 4592-573, 1995.
Elliott George C.
Larson Thomas G.
University of Massachusetts
LandOfFree
Oligonucleotides with anti-Epstein-Barr virus activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides with anti-Epstein-Barr virus activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides with anti-Epstein-Barr virus activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-885705